.svg)
RALEIGH,N.C., February 3, 2025 – Endpoint Clinical, a global leader in randomization and trial supply management (RTSM) solutions, today announced a major brand refresh, reflecting the next evolution of Endpoint. The new brand aspires to fully represent Endpoint’s customer-centric approach, built on 15 years of stability and innovation exclusively in the RTSM space.
Following its acquisition in June 2024 by Arsenal Capital Partners, a specialized private equity firm with a 24-year track record of building market-leading healthcare technology companies, Endpoint’s new brand arrives amid an accelerated expansion of its clinical trial solutions. As the industry’s only built-for-purpose RTSM, Endpoint complements its trusted trial stewardship with tech-enabled services, including study builds in four weeks or less (compared to industry standards of 8-16 weeks). In addition to an anticipatory stance on governance and compliance, Endpoint’s unique history exclusively in the RTSM space positions the team to redefine responsiveness, accountability, and vigilance in clinical trial management.
"There are two times when you should think about your RTSM,” Nagaraja Srivatsan, CEO of Endpoint Clinical, “when you’re choosing your RTSM partner and when you encounter change needs along the way. We’re thrilled about how our new brand elevates everything Endpoint does behind the scenes to enable our customers to forget about their RTSM and focus on the trial. Our expertly crafted services minimize friction, reduce risk, and ensure that the choices you make at the beginning of a study drive your success at every endpoint.”
"We’ve made big investments in our technology, but what really sets us apart is our team—industry experts who truly understand what’s at stake in clinical trials," added Jennifer Aquino, COO of Endpoint Clinical. "This brand refresh is a reminder that we’re not just here to check a box on innovation. We’re here to push RTSM forward with modern solutions and continuous support to keep studies on track."
The brand refresh also underscores Endpoint’s continued momentum. In the last six months, the company has strengthened its leadership team with seasoned industry experts, enhanced its quality processes, and evolved its core technology to provide even greater value to customers. Arsenal Capital Partners' investment further validates Endpoint’s unique position in the market, reinforcing its focus on delivering high-quality, innovative RTSM solutions.
Endpoint Clinical has more than 600 staff members globally and has supported over 2,000 studies across more than 90 countries, managing over 650,000 patients and 90,000 sites. With over 800 active studies, Endpoint brings deep expertise across all phases and levels of complexity.
Endpoint Clinical
Endpoint Clinical is a trusted clinical trial technology and service partner that delivers reliable RTSM solutions. Endpoint is committed to blending seamlessly into clinical trial processes by providing anticipatory and adaptive solutions to proactively mitigate risks. Endpoint’s decades of experience in the field guarantees a deep understanding of the problems manufacturers often face in clinical trials. Endpoint’s tech-forward dedication to innovation and investment enables the company to control the controllables and proactively generate speedy and strategic solutions, so manufacturers can focus on a seamless clinical trial. Read more about Endpoint’s solutions at https://www.endpointclinical.com/solutions/
Arsenal Capital Partners
Arsenal Capital Partners is a leading private equity investment firm that specializes in building market-leading industrial growth and healthcare companies. Since its inception in 2000, Arsenal has raised institutional equity investment funds totaling over $10 billion, completed more than 300 platform and add-on acquisitions, and achieved more than 35 realizations. The firm works with management teams to build strategically important companies with leading market positions, high growth and high value-add. For more information, visitwww.arsenalcapital.com.
Media Contact:
Keelie Truell
ktruell@endpointclinical.com